Osteonecrosis of the jaw – Prevention and treatment strategies for oral health professionals

Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy

“…It significantly compromises the quality of life of patients, causing infection, necrotic bone exposure, pain, halitosis, tooth mobility, impaired mastication and difficulty in speaking. [2][3][4] The definition of BRONJ has required necrotic bone exposure in the oral cavity as a diagnostic criterion. 5 However, recently, the occurrence of this disease without bone exposure has been extensively discussed.…”

Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis

“…5 Treatment planning is aggressive involving surgical debridement and it is necessary to discontinue the antiresorptive therapy, but this may compromise the cancer treatment. 5,6 It is essential to understand the pathogenesis of BRONJ based on experimental models because the existing treatments exhibit high-risk, low effectiveness and high aggressiveness. 2 Although low doses of BPs may cause BRONJ, it is most strongly associated with higher doses used in the treatment of bone metastases.…”

PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells

“…In fact, it has been reported that incidence of BRONJ ranges from 0.8-12 % of patients receiving IV bisphosphonates [7]. First described in 2003 [8], this condition is defined as exposed necrotic bone (indicating soft tissue recession) in the mandible or maxilla for a period of at least 8 weeks, without radiation to the head or neck in the patient's history [1,5,7].…”